This post was originally published on this site
Investing.com — Vaxxinity Inc (NASDAQ:VAXX) stock gained over 14.9% Wednesday after it said the first Parkinson’s disease patient has been dosed in Part B of the company’s Phase 1 clinical trial of UB-312.
The U.S. biotechnology moved on to dosing the first patient in Part B of the trial after completing Part A of the study in healthy volunteers. The “synthetic peptide” vaccine was granted an orphan designation for multiple system atrophy by the European Medical Agency.
Part B of the study will enroll up to 20 patients with Parkinson’s disease.
The study will also assess exploratory biomarker endpoints after receiving a Michael J. Fox Foundation grant.
“We are delighted to achieve another milestone for Vaxxinity as we initiate the next part of our clinical program in Parkinson’s, an indication with clear unmet needs for a large patient population,” commented Mei Mei Hu, CEO of Vaxxinity.
“Developing vaccines that target chronic and difficult-to-treat diseases like Parkinson’s are integral to our vision of providing cheaper, safer and more effective medicines to the world.”
